Michael D. Clayman, MD

The chief executive officer and co-founder of Flexion Therapeutics discussed the company’s pain-focused pipeline, which includes a gene therapy that targets inflammation.

Flexion Therapeutics believes that local administration of a gene therapy may not only improve pain management but potentially slow disease progression.